Kevin DAmour - Jun 28, 2021 Form 4 Insider Report for Brooklyn ImmunoTherapeutics, Inc. (ERNA)

Role: Chief Scientific Officer
Signature: /s/Bella Zaslavsky, Attorney-in-Fact for Kevin D'Amour
Stock symbol: ERNA
Transactions as of: Jun 28, 2021
Transactions value $: $0
Form type: 4
Date filed: 6/30/2021, 09:34 PM
Next filing: Mar 17, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ERNA	Stock Option	Award	$0	+141K		$0.00	141K	Jun 28, 2021	Common Stock	141K	$21.35	Direct	F1
transaction	ERNA	Restricted Stock Unit	Award	$0	+70.3K		$0.00	70.3K	Jun 28, 2021	Common Stock	70.3K		Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option vests and becomes exercisable over four years, with twenty-five percent of the shares covered thereby vesting on June 28, 2022, and 1/36 of the remaining shares covered thereby vesting on the 28th day of each calendar month from July 28, 2022 through June 28, 2025, subject to continued service through each vesting date.
F2	Each restricted stock unit represents a contingent right to receive one share of common stock.
F3	The Restricted Stock Unit vests and becomes exercisable in four equal installments on June 28 of each of 2022, 2023, 2024 and 2025, provided they shall vest in full immediately prior to a Change in Control (as defined in Dr. D'Amour's Executive Employment Agreement, dated as of June 5, 2021 and effective as of June 28, 2021), subject to continued service through each vesting date.

Remarks:

Chief Scientific Officer